Novartis Deepens Commitment to India with Launch of Pluvicto®, the Country’s First Regulatory Authority Approved Radioligand Therapy for Advanced Prostate Cancer
Novartis India has launched Pluvicto, the country’s first regulator-approved radioligand therapy for PSMA-positive prostate cancer. The treatment offers a targeted approach for metastatic cases, addressing a growing cancer burden among Indian men, with nearly 250,000 new cases reported annually.
Hyderabad: In a major advancement for cancer care in India, Novartis India announced the launch of Pluvicto (lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority approved radioligand therapy for eligible patients with Prostate-Specific Membrane Antigen (PSMA)-positive prostate cancer.
Designed to precisely target prostate cancer cells while minimizing exposure to healthy tissues, Pluvicto introduces a new treatment approach for metastatic prostate cancer, a disease that continues to place a significant physical and emotional burden on patients and families across India.
The launch comes at a time when prostate cancer is emerging as one of India’s fastest-growing cancer burdens among men. Prostate cancer is now among the top three cancers affecting urban men in India, with nearly 2,50,000 cases every year.
Approximately 50% of diagnosed patients present at a metastatic stage, where treatment becomes significantly more complex due to poorer prognosis, treatment-related side effects, and challenges in treatment sequencing.
